Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: VRTX REGN BIIB GILD INCY ALNY EXEL IONS SAGE ACAD

| Held by: VTI IJH VB VBK VXF MDY IBB XBI FBT IWP

Index	-	P/E	26.59	EPS (ttm)	4.67	Insider Own	2.67%	Shs Outstand	100.10M	Perf Week	-12.10%
Market Cap	12.46B	Forward P/E	16.49	EPS next Y	7.53	Insider Trans	-3.64%	Shs Float	97.69M	Perf Month	-8.28%
Enterprise Value	11.45B	PEG	0.60	EPS next Q	1.09	Inst Own	98.96%	Short Float	3.42%	Perf Quarter	-15.48%
Income	478.60M	P/S	4.35	EPS this Y	27.16%	Inst Trans	0.21%	Short Ratio	3.09	Perf Half Y	-5.48%
Sales	2.86B	P/B	3.82	EPS next Y	26.73%	ROA	11.13%	Short Interest	3.34M	Perf YTD	-12.49%
Book/sh	32.50	P/C	8.41	EPS next 5Y	27.58%	ROE	16.38%	52W High	160.18 -22.51%	Perf Year	6.20%
Cash/sh	14.75	P/FCF	16.64	EPS past 3/5Y	44.05% 2.31%	ROIC	13.05%	52W Low	84.23 47.36%	Perf 3Y	19.90%
Dividend Est.	-	EV/EBITDA	17.17	Sales past 3/5Y	24.32% 22.29%	Gross Margin	98.18%	Volatility	4.38% 3.12%	Perf 5Y	8.78%
Dividend TTM	-	EV/Sales	4.00	EPS Y/Y TTM	41.73%	Oper. Margin	22.25%	ATR (14)	4.60	Perf 10Y	244.40%
Dividend Ex-Date	-	Quick Ratio	3.30	Sales Y/Y TTM	21.45%	Profit Margin	16.73%	RSI (14)	30.92	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	3.39	EPS Q/Q	47.94%	SMA20	-8.35%	Beta	0.34	Target Price	177.29
Payout	0.00%	Debt/Eq	0.14	Sales Q/Q	28.33%	SMA50	-11.94%	Rel Volume	1.96	Prev Close	123.10
Employees	2000	LT Debt/Eq	0.13	Earnings	Feb 11 AMC	SMA200	-8.49%	Avg Volume	1.08M	Price	124.12
IPO	May 23, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.97% 1.90%	Trades		Volume	2,122,668	Change	0.83%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$175
Oct-21-25	Initiated	Citigroup	Buy	$175
Jul-21-25	Initiated	Truist	Buy	$163
Jul-10-25	Initiated	Goldman	Buy	$182
Apr-15-25	Upgrade	Needham	Hold → Buy	$138
Apr-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$137
Feb-11-25	Initiated	Deutsche Bank	Hold	$138
Oct-10-24	Resumed	Raymond James	Outperform	$155
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight	$131 → $159
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$140 → $170
Dec-13-23	Resumed	Citigroup	Neutral	$127
Dec-12-23	Initiated	Deutsche Bank	Buy	$136
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$135 → $140
Aug-21-23	Reiterated	Mizuho	Neutral	$112 → $113
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform	$115 → $125
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform	$91 → $96
May-04-23	Upgrade	Guggenheim	Neutral → Buy	$145
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$124 → $132
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform	$130
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$120 → $130

Show Previous Ratings

Feb-12-26 02:38PM	Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance (Benzinga) -10.43%
12:23PM	Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor (BioPharma Dive)
08:30AM	Neurocrine Biosciences, Inc. Q4 2025 Earnings Call Summary (Moby)
12:04AM	Neurocrine Biosciences Inc (NBIX) Q4 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Feb-11-26 06:39PM	Neurocrine Biosciences Q4 Earnings Call Highlights (MarketBeat)
05:30PM	Loading…
05:30PM	Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates (Zacks)
04:17PM	Neurocrine: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 (PR Newswire)
Feb-06-26 09:15AM	Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-05-26 10:00AM	Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:29AM	Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? (Zacks)
08:10AM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-04-26 10:00AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jan-26-26 08:30AM	Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia (PR Newswire)
12:10PM	Loading…
Jan-22-26 12:10PM	Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive? (Zacks)
Jan-21-26 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results (PR Newswire)
Jan-15-26 08:30AM	Neurocrine Biosciences Presents Head-to-Head INGREZZA (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR (PR Newswire)
Jan-08-26 04:10PM	How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine (Investor's Business Daily)
08:09AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Alphabet, Coinbase Global, Digital Realty Trust, Intuit, Reddit, Roku, Tyler Technologies, and More (24/7 Wall St.)
Jan-05-26 04:01PM	Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-22-25 04:05PM	Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy (PR Newswire)
Dec-16-25 04:01PM	Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology (PR Newswire)
Dec-09-25 04:01PM	Neurocrine Biosciences to Host R&D Day on December 16 (PR Newswire)
Dec-05-25 08:03AM	Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level (Investor's Business Daily)
Nov-27-25 12:45PM	Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now (Zacks)
Nov-26-25 04:11PM	Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied (Investor's Business Daily) +5.61%
Nov-20-25 08:30AM	Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA (valbenazine) Capsules (PR Newswire)
Nov-11-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
12:45PM	Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice (Zacks)
04:05PM	Loading…
Nov-10-25 04:05PM	Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder (PR Newswire)
01:25PM	Neurocrine chalks up a depression drug failure (BioPharma Dive)
Nov-06-25 12:20PM	Earnings Estimates Rising for Neurocrine (NBIX): Will It Gain? (Zacks)
Nov-04-25 12:00PM	What Makes Neurocrine (NBIX) a New Strong Buy Stock (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
Oct-30-25 04:15PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
03:21PM	Neurocrine Biosciences Inc (NBIX) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
01:13PM	Earnings roundup: Alnylams down day, Neurocrines head scratch and Biogens low quality win (BioPharma Dive)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
Oct-29-25 04:14PM	Why Neurocrine Stock Was Spooked Despite Its Big Quarterly Beat (Investor's Business Daily) -6.35%
Oct-28-25 09:03PM	Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock (24/7 Wall St.)
07:30PM	Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates (Zacks)
04:45PM	Neurocrine Shares Rise, But Pull Back From Steep Gains, On Strong Ingrezza Quarter (Investor's Business Daily)
04:19PM	Neurocrine Bio Surges After Crushing Third-Quarter Expectations (Investor's Business Daily)
04:06PM	Neurocrine: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Third Quarter 2025 Financial Results (PR Newswire)
Oct-24-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice (Zacks)
Oct-23-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) (Zacks)
Oct-22-25 05:15PM	USANA Health Sciences (USNA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-21-25 10:00AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-17-25 08:30AM	Neurocrine Biosciences Presents New KINECT 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA (valbenazine) 40 mg Capsules (PR Newswire)
Oct-07-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results (PR Newswire)
Oct-06-25 04:05PM	Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea (PR Newswire)
Sep-25-25 09:55AM	Should You be Optimistic on Neurocrine Biosciences (NBIX)? (Insider Monkey)
Sep-24-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Sep-23-25 08:30AM	Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden (PR Newswire)
Sep-22-25 08:30AM	Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder (PR Newswire)
Sep-16-25 04:05PM	Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 (PR Newswire)
02:58PM	What Does Wall Street Think About Neurocrine Biosciences (NBIX)? (Insider Monkey)
Sep-02-25 04:03AM	Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access (Insider Monkey)
Aug-26-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in September (PR Newswire)
Aug-20-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Aug-12-25 10:16AM	Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Aug-06-25 04:01PM	Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference (PR Newswire)
Jul-31-25 03:32AM	Neurocrine Biosciences Inc (NBIX) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) -6.24%
Jul-30-25 06:00PM	Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:05PM	Neurocrine: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Second Quarter 2025 Financial Results (PR Newswire)
Jul-28-25 11:40AM	CPRX vs. NBIX: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-27-25 09:58AM	Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence (Insider Monkey)
Jul-25-25 11:28PM	Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating (Insider Monkey)
Jul-24-25 10:00AM	Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-23-25 10:00AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-15-25 10:57AM	Neurocrine shares new one-year data from trial of Crenessity for CAH (Clinical Trials Arena)
09:00AM	Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Analysis of CAHtalog Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 (PR Newswire)
Jul-14-25 04:35PM	Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting (PR Newswire)
08:30AM	Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY (crinecerfont) in Adult Patients, at ENDO 2025 (PR Newswire)
Jul-10-25 11:26PM	Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim's Buy List (Insider Monkey)
08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
Jul-09-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results (PR Newswire)
Jun-30-25 04:05PM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist (PR Newswire)
Jun-29-25 08:36AM	3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (MarketBeat)
Jun-27-25 08:30AM	Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea (PR Newswire)
Jun-23-25 11:40AM	EGO or AEM: Which Is the Better Value Stock Right Now? (Zacks)
11:40AM	CPRX vs. NBIX: Which Stock Is the Better Value Option? (Zacks)
Jun-20-25 08:30AM	Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA (valbenazine) Capsules in Older Adults with Tardive Dyskinesia (PR Newswire)
Jun-17-25 06:20AM	Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? (Zacks)
Jun-12-25 06:20AM	Should You Invest in the SPDR S&P Biotech ETF (XBI)? (Zacks)
Jun-09-25 04:05PM	Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer (PR Newswire)
Jun-03-25 11:40AM	CPRX or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Jun-02-25 08:30AM	Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO Study Demonstrating INGREZZA (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia (PR Newswire)
May-30-25 04:30PM	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors (GlobeNewswire)
May-29-25 12:03AM	Neurocrine Biosciences, Inc. (NBIX)'s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched (Insider Monkey)
May-28-25 04:05PM	Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 (PR Newswire)
May-27-25 06:20AM	Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? (Zacks)

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boyer David W.	Chief Corp. Affairs Officer	Jan 31 '26	Option Exercise	0.00	2,096	0	5,902	Feb 03 06:22 PM
BENEVICH ERIC	Chief Commercial Officer	Jan 31 '26	Option Exercise	0.00	2,294	0	54,047	Feb 03 06:21 PM
ABERNETHY MATT	Chief Financial Officer	Jan 31 '26	Option Exercise	0.00	2,437	0	38,465	Feb 03 06:06 PM
Cooke Julie	Chief Human Resources Officer	Jan 31 '26	Option Exercise	0.00	1,741	0	28,599	Feb 03 06:05 PM
Delaet Ingrid	Chief Regulatory Officer	Jan 31 '26	Option Exercise	0.00	801	0	5,531	Feb 03 06:04 PM
Gano Kyle	Chief Executive Officer	Jan 31 '26	Option Exercise	0.00	2,927	0	143,334	Feb 03 06:03 PM
GORMAN KEVIN CHARLES	Director	Jan 31 '26	Option Exercise	0.00	5,142	0	519,738	Feb 03 06:02 PM
Lippoldt Darin	Chief Legal Officer	Jan 31 '26	Option Exercise	0.00	2,373	0	49,127	Feb 03 06:01 PM
Onyia Jude	Chief Scientific Officer	Jan 31 '26	Option Exercise	0.00	238	0	16,119	Feb 03 06:01 PM
Gano Kyle	Chief Executive Officer	Jan 16 '26	Option Exercise	35.99	36,400	1,310,036	174,995	Jan 20 06:56 PM
Gano Kyle	Chief Executive Officer	Jan 16 '26	Sale	132.70	36,400	4,830,458	140,407	Jan 20 06:56 PM
KYLE GANO	Officer	Jan 16 '26	Proposed Sale	133.35	36,400	4,853,940		Jan 16 04:21 PM
Lippoldt Darin	Chief Legal Officer	Jan 08 '26	Option Exercise	35.99	3,349	120,531	46,754	Jan 12 04:18 PM
Norwalk Leslie V	Director	Dec 15 '25	Option Exercise	91.07	10,000	910,742	12,429	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 15 '25	Sale	152.23	5,000	761,144	7,429	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 16 '25	Sale	155.09	1,190	184,558	6,239	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 15 '25	Proposed Sale	155.11	11,250	1,745,000		Dec 15 10:58 AM
Lippoldt Darin	Chief Legal Officer	Dec 08 '25	Option Exercise	43.24	4,376	189,218	47,781	Dec 10 09:04 AM
Lippoldt Darin	Chief Legal Officer	Dec 08 '25	Sale	159.65	4,376	698,615	43,405	Dec 10 09:04 AM
DARIN LIPPOLDT	Officer	Dec 08 '25	Proposed Sale	155.51	4,376	680,512		Dec 08 04:35 PM
LYONS GARY A	Director	Dec 03 '25	Option Exercise	47.89	15,000	718,350	135,482	Dec 04 04:14 PM
LYONS GARY A	Director	Dec 03 '25	Sale	152.61	15,000	2,289,082	120,482	Dec 04 04:14 PM
GARY A LYONS REVOCABLE LIVING	Director	Dec 03 '25	Proposed Sale	152.48	15,000	2,287,200		Dec 03 04:36 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 28 '25	Option Exercise	35.99	5,970	214,860	50,863	Dec 02 05:21 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 28 '25	Sale	151.74	5,970	905,881	44,893	Dec 02 05:21 PM
Onyia Jude	Chief Scientific Officer	Nov 29 '25	Option Exercise	0.00	4,426	0	18,129	Dec 02 05:14 PM
ERIC BENEVICH	Officer	Nov 28 '25	Proposed Sale	151.58	5,970	904,933		Nov 28 01:20 PM
MORROW GEORGE J	Director	Nov 25 '25	Option Exercise	47.89	15,000	718,350	22,068	Nov 26 04:28 PM
MORROW GEORGE J	Director	Nov 25 '25	Sale	143.37	15,000	2,150,512	7,068	Nov 26 04:28 PM
GEORGE MORROW	Director	Nov 25 '25	Proposed Sale	141.25	15,000	2,118,750		Nov 25 04:25 PM
RASTETTER WILLIAM H	Director	Nov 05 '25	Option Exercise	47.89	18,000	862,020	58,360	Nov 06 05:25 PM
RASTETTER WILLIAM H	Director	Nov 05 '25	Sale	151.82	18,000	2,732,690	40,360	Nov 06 05:25 PM
Gano Kyle	Officer	Nov 04 '25	Proposed Sale	141.97	300	42,591		Nov 05 09:09 PM
WILLIAM H. RASTETTER	Director	Nov 05 '25	Proposed Sale	143.19	18,000	2,577,420		Nov 05 04:19 PM
Gano Kyle	Chief Executive Officer	Nov 01 '25	Option Exercise	0.00	613	0	140,720	Nov 04 08:18 PM
Gano Kyle	Chief Executive Officer	Nov 04 '25	Sale	141.97	300	42,591	140,407	Nov 04 08:18 PM
GORMAN KEVIN CHARLES	Director	Aug 07 '25	Option Exercise	35.99	106,322	3,826,529	620,918	Aug 11 04:55 PM
GORMAN KEVIN CHARLES	Director	Aug 07 '25	Sale	126.41	106,322	13,440,281	514,596	Aug 11 04:55 PM
KEVIN CHARLES GORMAN	Director	Aug 07 '25	Proposed Sale	128.43	106,322	13,654,934		Aug 07 04:24 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Option Exercise	79.02	457	36,112	5,187	Jul 11 05:15 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Sale	135.00	457	61,695	4,730	Jul 11 05:15 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Option Exercise	84.74	59,819	5,069,062	78,108	Jul 11 05:01 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Sale	130.46	59,819	7,803,688	18,289	Jul 11 05:01 PM
INGRID DELAET	Officer	Jul 10 '25	Proposed Sale	133.51	457	61,014		Jul 10 04:32 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Option Exercise	84.74	20,362	1,725,476	38,651	Jul 07 04:10 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Sale	130.13	20,362	2,649,738	18,289	Jul 07 04:10 PM
JUDE ONYIA	Officer	Jul 02 '25	Proposed Sale	128.00	80,181	10,263,168		Jul 02 04:22 PM
GORMAN KEVIN CHARLES	Director	May 27 '25	Sale	120.38	9,613	1,157,211	514,596	May 29 06:15 PM
KEVIN CHARLES GORMAN	Director	May 27 '25	Proposed Sale	120.18	9,613	1,155,290		May 27 04:38 PM
RASTETTER WILLIAM H	Director	May 22 '25	Option Exercise	0.00	2,869	0	40,360	May 22 06:15 PM
POON CHRISTINE A	Director	May 22 '25	Option Exercise	0.00	1,435	0	1,435	May 22 05:32 PM
Sharp Shalini	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:28 PM
SHERWIN STEPHEN A	Director	May 22 '25	Option Exercise	0.00	2,869	0	13,542	May 22 05:26 PM
POPS RICHARD F	Director	May 22 '25	Option Exercise	0.00	2,869	0	34,480	May 22 05:23 PM
MORROW GEORGE J	Director	May 22 '25	Option Exercise	0.00	2,869	0	7,068	May 22 05:20 PM
LYONS GARY A	Director	May 22 '25	Option Exercise	0.00	1,435	0	120,482	May 22 05:18 PM
Norwalk Leslie V	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:14 PM
Mercier Johanna	Director	May 22 '25	Option Exercise	0.00	1,435	0	3,535	May 22 05:12 PM
Cooke Julie	Chief Human Resources Officer	May 16 '25	Option Exercise	61.82	6,468	399,852	26,858	May 20 04:43 PM
RASTETTER WILLIAM H	Director	May 05 '25	Option Exercise	42.76	30,000	1,282,800	67,491	May 07 07:05 PM
RASTETTER WILLIAM H	Director	May 05 '25	Sale	110.20	30,000	3,305,952	37,491	May 07 07:05 PM
WILLIAM H. RASTETTER	Officer	May 05 '25	Proposed Sale	109.68	30,000	3,290,400		May 05 04:40 PM

Open in Screener

TVTX

Travere Therapeutics Inc

Feb 13 • 04:00PM ET

27.82

-2.78 -9.08 %

Healthcare • Biotechnology • USA • NASD

TVTX Travere Therapeutics Inc daily Stock Chart

Peers: BMRN RARE SRPT VYGR FOLD QURE CRSP AGIO CLLS PFE

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA VHT PJP

Index	RUT	P/E	-	EPS (ttm)	-1.08	Insider Own	2.05%	Shs Outstand	89.46M	Perf Week	-6.36%
Market Cap	2.49B	Forward P/E	32.46	EPS next Y	0.86	Insider Trans	-23.37%	Shs Float	87.64M	Perf Month	-3.84%
Enterprise Value	2.56B	PEG	-	EPS next Q	0.00	Inst Own	117.95%	Short Float	16.54%	Perf Quarter	-23.72%
Income	-88.54M	P/S	5.71	EPS this Y	91.78%	Inst Trans	2.11%	Short Ratio	7.05	Perf Half Y	52.61%
Sales	435.83M	P/B	33.83	EPS next Y	355.59%	ROA	-16.98%	Short Interest	14.49M	Perf YTD	-27.19%
Book/sh	0.82	P/C	9.78	EPS next 5Y	-	ROE	-410.78%	52W High	42.13 -33.97%	Perf Year	17.28%
Cash/sh	2.84	P/FCF	-	EPS past 3/5Y	-10.63% -3.34%	ROIC	-22.27%	52W Low	12.91 115.49%	Perf 3Y	31.16%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	0.83% 5.87%	Gross Margin	85.08%	Volatility	6.49% 5.68%	Perf 5Y	5.46%
Dividend TTM	-	EV/Sales	5.88	EPS Y/Y TTM	77.02%	Oper. Margin	-20.59%	ATR (14)	1.98	Perf 10Y	98.71%
Dividend Ex-Date	-	Quick Ratio	2.71	Sales Y/Y TTM	114.22%	Profit Margin	-20.32%	RSI (14)	36.26	Recom	1.27
Dividend Gr. 3/5Y	- -	Current Ratio	2.75	EPS Q/Q	135.55%	SMA20	-7.63%	Beta	0.81	Target Price	42.29
Payout	-	Debt/Eq	4.48	Sales Q/Q	162.11%	SMA50	-16.26%	Rel Volume	1.49	Prev Close	30.60
Employees	385	LT Debt/Eq	4.40	Earnings	Feb 19 AMC	SMA200	12.77%	Avg Volume	2.06M	Price	27.82
IPO	Oct 06, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	192.20% 56.70%	Trades		Volume	3,062,236	Change	-9.08%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-25	Reiterated	Citigroup	Buy	$34 → $48
Jun-11-25	Resumed	H.C. Wainwright	Buy	$30
Jun-11-25	Reiterated	Citigroup	Buy	$35 → $32
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$9 → $27
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy	$25
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Nov-20-23	Initiated	Citigroup	Neutral	$7
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $8
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform	$30
Jul-21-23	Initiated	JP Morgan	Overweight	$26
Jun-07-23	Resumed	Piper Sandler	Neutral	$22
May-22-23	Initiated	TD Cowen	Outperform	$30
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy	$37
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform	$30
Dec-14-22	Initiated	Stifel	Hold	$22

Show Previous Ratings

Feb-12-26 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results (Business Wire) -9.08%
10:00AM	Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-11-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-04-26 04:30PM	Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit (Business Wire) -6.98%
Jan-28-26 05:35PM	Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +5.65%
09:52PM	Loading…
Jan-22-26 09:52PM	BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari (Insider Monkey) +5.24%
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-14-26 10:54AM	TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA (Zacks)
06:44AM	Travere Stock Slips After FDA Delays Review Of Key Kidney Drug (Benzinga)
Jan-13-26 07:51PM	Why Travere Therapeutics Stock Got Trounced on Tuesday (Motley Fool) -14.63%
04:36PM	Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug (Investor's Business Daily)
04:35PM	Stocks Fall on Weakness in Software and Credit Card Companies (Barchart)
01:24PM	Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI (sparsentan) in FSGS (Business Wire)
11:19AM	Options Bears Eye Plummeting Biotech Stock (Schaeffer's Research)
11:17AM	Stock Indexes Slip as the Magnificent Seven Technology Stocks Retreat (Barchart)
09:54AM	Loading…
09:54AM	Travere Therapeutics Hammered On A Potential, Surprise Delay For Filspari (Investor's Business Daily)
Jan-12-26 05:00PM	Travere Therapeutics Provides Corporate Update and 2026 Outlook (Business Wire)
Jan-05-26 04:30PM	Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) -6.06%
Dec-25-25 10:44AM	Dow Jones, S&P 500 Hit Record Highs. Stock Market Closed For Christmas. (Investor's Business Daily)
Dec-24-25 06:51PM	Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday (Motley Fool) +13.91%
04:40PM	Nvidia Buying AI Chip Startup Groq In Record $20 Billion Deal: CNBC (Investor's Business Daily)
01:40PM	Dow Jones, S&P 500 Hit Record Highs Heading Into Christmas Holiday (Investor's Business Daily)
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-26-25 08:00AM	Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 (Investor's Business Daily)
Nov-10-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.31% +5.03%
Nov-06-25 11:00AM	Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025 (Business Wire)
Nov-04-25 05:23PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
Nov-03-25 01:34AM	Travere Therapeutics (TVTX) Climbs 25% on Impressive Earnings (Insider Monkey)
Nov-01-25 02:48PM	Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook (Insider Monkey)
07:35PM	Loading…
Oct-31-25 07:35PM	Closing Bell Movers: Amazon soars to all-time highs on earnings (TipRanks) +18.58%
04:06PM	Top 2% Travere Catapults To Profit-Taking Zone After Screaming Up Another Beat (Investor's Business Daily)
Oct-30-25 11:02PM	Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Call Highlights: Strong FILSPARI Sales and ... (GuruFocus.com)
06:30PM	Travere (TVTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:55PM	Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:51PM	Travere: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-29-25 09:41AM	Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-27-25 06:58AM	Chugai acquires Renalys, enhancing its kidney disease portfolio (Pharmaceutical Technology) +6.09%
Oct-24-25 04:58AM	Chugai buys a kidney biotech; ICER targets rising launch prices (BioPharma Dive)
Oct-23-25 04:30PM	Travere Therapeutics to Report Third Quarter 2025 Financial Results (Business Wire)
12:22PM	Biotech Leader Travere Therapeutics Eyes Buy Point After More Than Doubling (Investor's Business Daily)
Oct-17-25 09:01AM	Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025 (Business Wire)
Oct-16-25 08:50AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug (Zacks)
Oct-15-25 12:00PM	What Makes Travere (TVTX) a New Strong Buy Stock (Zacks)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)
Oct-10-25 05:11PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-26-25 07:00AM	CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy (Business Wire)
Sep-18-25 09:38AM	Target initiated, Nike upgraded: Wall Street's top analyst calls (The Fly)
Sep-12-25 01:16PM	Hims & Hers Leads 14 Growth Stocks Amid Medical Boom (Investor's Business Daily) -6.12%
Sep-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.46%
10:40AM	TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA (Zacks)
09:15AM	Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside (Insider Monkey)
04:57AM	Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? (Zacks)
Sep-10-25 11:17AM	Stock Market Today: Inflation Data Hits Dow; Oracle Soars As This Biotech Zooms (Live Coverage) (Investor's Business Daily) +26.20%
09:13AM	Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High (Investor's Business Daily)
07:01AM	Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI (sparsentan) in FSGS (Business Wire)
Sep-03-25 07:01AM	Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism (Business Wire) +8.04%
Aug-28-25 10:00AM	Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch (Investor's Business Daily)
Aug-27-25 05:09PM	Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI (sparsentan) in IgA Nephropathy (Business Wire)
Aug-17-25 11:41PM	Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts (Insider Monkey)
Aug-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-25 09:06AM	Travere Therapeutics price target raised to $32 from $30 at Wedbush (TipRanks)
Aug-06-25 06:00PM	Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings (Zacks)
05:15PM	Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:13PM	Travere: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-05-25 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
09:54AM	Earnings To Watch: Travere Therapeutics Inc (TVTX) Reports Q2 2025 Result (GuruFocus.com)
Jul-31-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-30-25 04:30PM	Travere Therapeutics to Report Second Quarter 2025 Financial Results (Business Wire)
Jul-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-06-25 04:15AM	Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX) (Insider Monkey)
Jun-24-25 12:46PM	Travere Therapeutics Kicks Off "Play It Forward" Campaign for FSGS Awareness (Insider Monkey) +5.18%
Jun-13-25 02:02PM	HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs (Insider Monkey)
Jun-12-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-11-25 07:01AM	Travere Therapeutics to Present New FILSPARI (sparsentan) Data at the 15th International Podocyte Conference (Business Wire)
Jun-10-25 07:00AM	Travere Therapeutics Launches 'Play It Forward' Campaign to Celebrate the FSGS Community on Inaugural Awareness Day (Business Wire)
Jun-03-25 04:30PM	Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress (Business Wire)
May-23-25 04:00AM	England's NICE recommends FILSPARI (sparsentan) as a treatment option for IgA nephropathy (PR Newswire)
May-15-25 04:05PM	Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI (sparsentan) in FSGS (Business Wire) -20.57%
May-13-25 04:05PM	Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results (GlobeNewswire)
May-12-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.59%
May-07-25 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
May-01-25 11:07PM	Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:30PM	Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics (Zacks)
05:15PM	Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Travere Therapeutics Reports First Quarter 2025 Financial Results (Business Wire)
Apr-29-25 07:01AM	Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI (sparsentan) for IgA Nephropathy (Business Wire)
02:00AM	CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI in IgA Nephropathy (PR Newswire)
Apr-28-25 10:00AM	Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) +5.62%
Apr-24-25 04:30PM	Travere Therapeutics to Report First Quarter 2025 Financial Results (Business Wire) +5.57%
Apr-12-25 10:20AM	Travere Therapeutics price target lowered to $30 from $32 at Scotiabank (TipRanks)
Apr-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.49%
Apr-07-25 03:27AM	Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock? (Zacks)
Mar-31-25 04:30PM	Travere Therapeutics to Present New FILSPARI (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 (Business Wire) -8.94%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-26-25 09:39PM	Is Travere Therapeutics, Inc. (NASDAQ:TVTX) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
07:00AM	Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer (GlobeNewswire)

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 04 '26	Sale	32.21	1,779	57,295	105,706	Feb 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 04 '26	Sale	32.19	1,745	56,168	111,226	Feb 05 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Feb 04 '26	Sale	32.18	2,994	96,359	105,211	Feb 05 04:05 PM
ELIZABETH REED	Officer	Feb 04 '26	Proposed Sale	32.18	2,994	96,360		Feb 04 04:07 PM
JULA INRIG	Officer	Feb 04 '26	Proposed Sale	32.21	1,779	57,299		Feb 04 04:06 PM
CHRISTOPHER CLINE	Officer	Feb 04 '26	Proposed Sale	32.19	1,745	56,166		Feb 04 04:01 PM
Peter Heerma	Officer	Feb 03 '26	Proposed Sale	32.12	7,310	234,799		Feb 04 06:00 AM
Elizabeth E. Reed	Officer	Feb 03 '26	Proposed Sale	32.12	7,175	230,464		Feb 03 09:59 PM
Sandra Calvin	Officer	Feb 03 '26	Proposed Sale	32.12	4,333	139,177		Feb 03 09:58 PM
Christopher Cline	Officer	Feb 03 '26	Proposed Sale	32.12	7,242	232,616		Feb 03 09:45 PM
Jula Inrig	Officer	Feb 03 '26	Proposed Sale	32.12	6,956	223,429		Feb 03 09:37 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 03 '26	Sale	32.28	100,087	3,230,316	432,886	Feb 03 09:30 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 03 '26	Sale	32.12	6,956	223,427	107,485	Feb 03 09:30 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 03 '26	Sale	32.12	7,242	232,613	112,971	Feb 03 09:30 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Feb 03 '26	Sale	32.12	7,310	234,797	131,823	Feb 03 09:30 PM
ROTE WILLIAM E.	Chief Research Officer	Feb 03 '26	Sale	32.87	12,446	409,100	109,087	Feb 03 09:30 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Feb 03 '26	Sale	32.12	4,333	139,176	49,080	Feb 03 09:30 PM
REED ELIZABETH E	Chief Legal Officer and GC	Feb 03 '26	Sale	32.12	7,175	230,461	108,205	Feb 03 09:30 PM
Dube Eric M	Officer	Feb 03 '26	Proposed Sale	32.87	100,087	3,289,860		Feb 03 11:38 AM
ROTE WILLIAM E.	Officer	Feb 03 '26	Proposed Sale	32.87	12,446	409,100		Feb 03 10:05 AM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 27 '26	Option Exercise	15.46	51,865	801,833	471,038	Jan 27 08:25 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 23 '26	Option Exercise	15.46	8,135	125,767	427,308	Jan 27 08:25 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 27 '26	Sale	30.10	51,865	1,560,981	419,173	Jan 27 08:25 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 23 '26	Sale	30.01	8,135	244,153	419,173	Jan 27 08:25 PM
Dube Eric M	Officer	Jan 27 '26	Proposed Sale	30.10	51,865	1,560,982		Jan 27 04:05 PM
Dube Eric M	Officer	Jan 23 '26	Proposed Sale	30.01	8,135	244,153		Jan 23 04:14 PM
REED ELIZABETH E	Chief Legal Officer and GC	Jan 20 '26	Option Exercise	19.08	10,000	190,800	100,270	Jan 21 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Jan 20 '26	Sale	27.34	10,000	273,420	90,270	Jan 21 04:05 PM
ELIZABETH REED	Officer	Jan 20 '26	Proposed Sale	27.34	10,000	273,420		Jan 20 04:04 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jan 05 '26	Sale	40.18	2,031	81,606	86,756	Jan 07 04:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jan 06 '26	Sale	37.75	445	16,799	86,311	Jan 07 04:05 PM
JULA INRIG	Officer	Jan 06 '26	Proposed Sale	37.75	445	16,799		Jan 06 04:07 PM
Jula Inrig	Officer	Jan 05 '26	Proposed Sale	40.18	2,031	81,606		Jan 05 07:49 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Dec 24 '25	Sale	40.00	4,980	199,200	113,013	Dec 29 09:11 PM
ROTE WILLIAM E.	Chief Research Officer	Dec 24 '25	Option Exercise	20.61	60,000	1,236,600	161,443	Dec 29 09:05 PM
ROTE WILLIAM E.	Chief Research Officer	Dec 24 '25	Sale	40.10	60,000	2,406,180	101,443	Dec 29 09:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Dec 24 '25	Option Exercise	8.93	15,000	133,950	103,787	Dec 29 09:01 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Dec 24 '25	Sale	42.00	15,000	630,004	88,787	Dec 29 09:01 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Dec 24 '25	Sale	40.00	7,402	296,080	38,233	Dec 29 08:59 PM
JULA INRIG	Officer	Dec 24 '25	Proposed Sale	42.00	15,000	630,004		Dec 29 09:39 AM
SANDRA CALVIN	Officer	Dec 24 '25	Proposed Sale	40.00	7,402	296,080		Dec 29 09:38 AM
Heerma Peter	Officer	Dec 24 '25	Proposed Sale	40.00	4,980	199,200		Dec 29 06:58 AM
ROTE WILLIAM E.	Officer	Dec 24 '25	Proposed Sale	40.10	60,000	2,406,179		Dec 29 06:28 AM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Dec 15 '25	Sale	36.00	2,910	104,760	45,635	Dec 16 04:23 PM
SANDRA CALVIN	Officer	Dec 15 '25	Proposed Sale	36.00	2,910	104,760		Dec 15 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Dec 01 '25	Option Exercise	16.23	20,000	324,600	112,083	Dec 03 04:30 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Dec 01 '25	Sale	35.01	20,000	700,202	92,083	Dec 03 04:30 PM
CHRISTOPHER CLINE	Officer	Dec 01 '25	Proposed Sale	35.01	20,000	700,200		Dec 01 04:09 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 04 '25	Option Exercise	24.02	61,250	1,471,212	115,660	Nov 06 04:05 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 04 '25	Sale	36.00	67,115	2,416,140	48,545	Nov 06 04:05 PM
SANDRA CALVIN	Officer	Nov 04 '25	Proposed Sale	36.00	67,115	2,416,140		Nov 04 04:14 PM
Coughlin Timothy	Director	Oct 31 '25	Option Exercise	16.95	18,000	305,040	73,500	Nov 04 04:05 PM
Coughlin Timothy	Director	Oct 31 '25	Sale	35.03	18,000	630,601	55,500	Nov 04 04:05 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Oct 31 '25	Sale	35.00	5,591	195,685	119,071	Nov 04 04:05 PM
Coughlin Timothy	Director	Oct 31 '25	Proposed Sale	34.98	18,000	629,693		Oct 31 04:05 PM
Heerma Peter	Officer	Oct 31 '25	Proposed Sale	35.00	5,591	195,685		Oct 31 02:51 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 28 '25	Option Exercise	15.46	92,872	1,435,801	512,045	Oct 30 04:45 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 29 '25	Option Exercise	15.46	27,128	419,399	446,301	Oct 30 04:45 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 28 '25	Sale	30.38	92,872	2,821,358	419,173	Oct 30 04:45 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 29 '25	Sale	30.12	27,128	817,074	419,173	Oct 30 04:45 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Oct 28 '25	Sale	30.00	2,662	79,860	124,662	Oct 30 04:45 PM
Dube Eric M	Officer	Oct 29 '25	Proposed Sale	30.12	27,128	817,045		Oct 29 04:26 PM
Dube Eric M	Officer	Oct 28 '25	Proposed Sale	30.38	92,872	2,821,217		Oct 28 04:57 PM
Heerma Peter	Officer	Oct 28 '25	Proposed Sale	30.00	2,662	79,860		Oct 28 02:08 PM
REED ELIZABETH E	Chief Legal Officer and GC	Sep 22 '25	Option Exercise	19.08	10,000	190,800	99,878	Sep 24 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Sep 22 '25	Sale	25.00	10,000	250,000	89,878	Sep 24 04:05 PM
ELIZABETH REED	Officer	Sep 22 '25	Proposed Sale	25.00	10,000	250,000		Sep 22 04:02 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 03 '25	Sale	18.20	454	8,263	92,202	Sep 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 04 '25	Sale	19.71	119	2,345	92,083	Sep 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Aug 27 '25	Sale	17.31	470	8,136	92,656	Aug 28 04:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jul 01 '25	Sale	14.65	815	11,940	88,787	Jul 02 05:28 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	May 05 '25	Sale	21.05	1,784	37,553	93,126	May 05 09:54 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	May 05 '25	Sale	21.05	18,924	398,350	419,173	May 05 09:53 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	May 05 '25	Sale	21.05	1,771	37,280	128,215	May 05 09:53 PM
ROTE WILLIAM E.	Chief Research Officer	May 05 '25	Sale	21.05	3,198	67,318	100,241	May 05 09:52 PM
REED ELIZABETH E	Chief Legal Officer and GC	May 05 '25	Sale	21.05	4,920	103,566	89,482	May 05 09:51 PM
Christopher Cline	Officer	May 05 '25	Proposed Sale	21.05	1,784	37,553		May 05 07:45 PM
Peter Heerma	Officer	May 05 '25	Proposed Sale	21.05	1,771	37,280		May 05 07:41 PM
REED ELIZABETH E	Officer	May 05 '25	Proposed Sale	21.05	4,920	103,566		May 05 11:32 AM
Dube Eric M	Officer	May 05 '25	Proposed Sale	21.05	18,924	398,350		May 05 11:20 AM
ROTE WILLIAM E.	Officer	May 05 '25	Proposed Sale	21.05	3,198	67,318		May 05 10:08 AM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 11 '25	Sale	13.14	48	631	89,990	Apr 14 06:23 PM
Christopher Cline	Officer	Apr 11 '25	Proposed Sale	13.14	48	631		Apr 11 07:03 PM

NBIX

Neurocrine Biosciences, Inc

TVTX

Travere Therapeutics Inc

Upgrade your FINVIZ experience